Regulus Therapeutics Inc.Regulus Therapeutics Inc.Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪132.24 M‬USD
−1.46USD
‪−30.04 M‬USD
‪52.90 M‬
Beta (1Y)
1.91

About Regulus Therapeutics Inc.

CEO
Joseph P. Hagan
Headquarters
San Diego
Employees (FY)
30
Founded
2007
FIGI
BBG000R33DR2
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of RGLS is 2.02 USD — it has increased by 5.21% in the past 24 hours. Watch Regulus Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Regulus Therapeutics Inc. stocks are traded under the ticker RGLS.
RGLS stock has fallen by 1.46% compared to the previous week, the month change is a 11.79% fall, over the last year Regulus Therapeutics Inc. has showed a 47.45% increase.
We've gathered analysts' opinions on Regulus Therapeutics Inc. future price: according to them, RGLS price has a max estimate of 11.00 USD and a min estimate of 3.00 USD. Watch RGLS chart and read a more detailed Regulus Therapeutics Inc. stock forecast: see what analysts think of Regulus Therapeutics Inc. and suggest that you do with its stocks.
RGLS reached its all-time high on Nov 10, 2014 with the price of 3072.00 USD, and its all-time low was 0.76 USD and was reached on Mar 20, 2023. View more price dynamics on RGLS chart.
See other stocks reaching their highest and lowest prices.
RGLS stock is 6.25% volatile and has beta coefficient of 1.91. Track Regulus Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Regulus Therapeutics Inc. there?
Today Regulus Therapeutics Inc. has the market capitalization of ‪132.24 M‬, it has increased by 5.16% over the last week.
Yes, you can track Regulus Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Regulus Therapeutics Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
RGLS earnings for the last quarter are −0.29 USD per share, whereas the estimation was −0.22 USD resulting in a −30.34% surprise. The estimated earnings for the next quarter are −0.13 USD per share. See more details about Regulus Therapeutics Inc. earnings.
Regulus Therapeutics Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 0 USD.
RGLS net income for the last quarter is ‪−8.47 M‬ USD, while the quarter before that showed ‪−8.06 M‬ USD of net income which accounts for −5.06% change. Track more Regulus Therapeutics Inc. financial stats to get the full picture.
No, RGLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 25, 2024, the company has 30.00 employees. See our rating of the largest employees — is Regulus Therapeutics Inc. on this list?
Like other stocks, RGLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Regulus Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Regulus Therapeutics Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Regulus Therapeutics Inc. stock shows the sell signal. See more of Regulus Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.